RA_Capital_Management Sells Vor_Biopharma Stock

RA Capital Management, a director of Vor Biopharma, has been consistently selling large quantities of Vor Biopharma stock throughout April. These transactions, disclosed in SEC filings, involved millions of dollars worth of shares and significantly reduced RA Capital Management's ownership stake in Vor Biopharma. For example, on April 20th, 171,963 shares were sold for over $2.7 million, and on April 22nd, another 165,150 shares were sold for over $2.6 million. These sales occurred at average prices ranging from $15.75 to $18.23 per share. Despite these substantial sales, several Wall Street analysts, including Wells Fargo, Citigroup, and Toronto-Dominion Bank — TD Cowen, have initiated or maintained 'buy' or 'overweight' ratings on Vor Biopharma, with price targets as high as $50.00. However, some, like H.C. Wainwright & Co. and Wedbush Securities, have adjusted their price targets or ratings to be more cautious. Vor Biopharma, a clinical-stage biotechnology company, is focused on developing allogeneic cell therapies for hematologic malignancies, with its lead program VOR33 targeting acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).